Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 548

Sort by

Sort Order Select

Journal Articles

Measurable residual disease intervention in AML: a new therapeutic horizon

Andrew H. Wei, Harry J. Iland, Courtney D. DiNardo, John Reynolds

Blood (2026) 147 (1): 13–23.

https://doi.org/10.1182/blood.2025029010

Published: 2026

Journal Articles

FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML

Blood (2025) 146 (21): 2608–2611.

https://doi.org/10.1182/blood.2025029391

Published: 2025

Includes: Supplemental data

Journal Articles

Restoring p53 wild-type conformation in TP53 -Y220C–mutant acute myeloid leukemia

Bing Z. Carter, Po Yee Mak, Edward Ayoub, Xiaogang Wu, Baozhen Ke, Yuki Nishida, Andrew Futreal, Lauren B. Ostermann, Andrea D. Bedoy, Steffen Boettcher, Courtney D. DiNardo, Anna Puzio-Kuter, Masha V. Poyurovsky, Arnold Levine, Michael Andreeff

Blood (2025) 146 (21): 2574–2588.

https://doi.org/10.1182/blood.2025028935

Published: 2025

Includes: Supplemental data

Journal Articles

Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy

Blood blood.2024027948.

https://doi.org/10.1182/blood.2024027948

Published: 2025

Includes: Supplemental data

Journal Articles

BLAST: a globally applicable and molecularly versatile survival model for chronic myelomonocytic leukemia

Blood (2025) 146 (7): 874–886.

https://doi.org/10.1182/blood.2024027170

Published: 2025

Includes: Supplemental data

Journal Articles

Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes

Blood (2025) 145 (25): 3015–3029.

https://doi.org/10.1182/blood.2024027244

Published: 2025

Includes: Supplemental data

Journal Articles

How I treat acute myeloid leukemia with differentiation therapy

Ghayas C. Issa, Eytan M. Stein, Courtney D. DiNardo

Blood (2025) 145 (12): 1251–1259.

https://doi.org/10.1182/blood.2024024008

Published: 2025

Journal Articles

Clonal landscape and clinical outcomes of telomere biology disorders: somatic rescue and cancer mutations

Blood (2024) 144 (23): 2402–2416.

https://doi.org/10.1182/blood.2024025023

Published: 2024

Includes: Supplemental data

Journal Articles

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Blood (2024) 144 (21): 2169–2173.

https://doi.org/10.1182/blood.2024025409

Published: 2024

Journal Articles

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

Hartmut Döhner, Keith W. Pratz, Courtney D. DiNardo, Andrew H. Wei, Brian A. Jonas, Vinod A. Pullarkat, Michael J. Thirman, Christian Récher, Andre C. Schuh, Sunil Babu, Xiaotong Li, Grace Ku, Zihuan Liu, Yan Sun, Jalaja Potluri, Monique Dail, Brenda Chyla, Daniel A. Pollyea

Blood (2024) 144 (21): 2211–2222.

https://doi.org/10.1182/blood.2024024944

Published: 2024

Includes: Supplemental data

Journal Articles

Causes of Death in Patients with Myelodysplastic Syndrome and Spliceosome Mutations

Arjun S. Peddireddy, Panayiotis Kontoyiannis, Koji Sasaki, Kelly S. Chien, Jayastu Senapati, Guillermo Montalban-Bravo, Courtney D. DiNardo, Gautam Borthakur, Rashmi Kanagal-Shamanna, Carlos E. Bueso-Ramos, Sherry Pierce, Hagop M. Kantarjian, Guillermo Garcia-Manero, Samuel Urrutia

Blood (2024) 144 (Supplement 1): 6704.

https://doi.org/10.1182/blood-2024-202540

Published: 2024

Journal Articles

Impact of Flow Cytometry-Based Measurable Residual Disease Clearance Kinetics in Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy

Wei-Ying Jen, Koji Sasaki, Farhad Ravandi, Tapan M. Kadia, Sa A. Wang, Wei Wang, Sanam Loghavi, Naval Daver, Courtney D. DiNardo, Ghayas C. Issa, Hussein A. Abbas, Cedric Nasnas, Alex Bataller, Samuel Urrutia, Sherry Pierce, Hagop M. Kantarjian, Nicholas J. Short

Blood (2024) 144 (Supplement 1): 1572.

https://doi.org/10.1182/blood-2024-212036

Published: 2024

Journal Articles

Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax

Jennifer Marvin-Peek, Hagop M. Kantarjian, Wei-Ying Jen, Gautam Borthakur, Naval Daver, Abhishek Maiti, Nicholas J. Short, Steven M. Kornblau, Naveen Pemmaraju, Eitan Kugler, Alexandre Bazinet, Yesid Alvarado-Valero, Hussein A. Abbas, Guillermo Garcia-Manero, Uday Popat, Elizabeth J. Shpall, Farhad Ravandi, Courtney D. DiNardo, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 3572.

https://doi.org/10.1182/blood-2024-202414

Published: 2024

Journal Articles

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

Blood (2024) 144 (Supplement 1): 4263.

https://doi.org/10.1182/blood-2024-204296

Published: 2024

Journal Articles

Final Results of a Phase II Study of Uproleselan Combined with Cladribine and Low-Dose Cytarabine for Patients with Treated Secondary Acute Myeloid Leukemia (ts-AML)

Caitlin R Rausch, Emmanuel Almanza-Huante, Wei-Ying Jen, Guillermo Montalban-Bravo, Farhad Ravandi, Kelly S. Chien, Nicholas J. Short, Naval Daver, Courtney D. DiNardo, Abhishek Maiti, Joseph E. Jabbour, Ghayas C. Issa, Guillermo Garcia-Manero, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 4262.

https://doi.org/10.1182/blood-2024-203831

Published: 2024

Journal Articles

Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods

Blood (2024) 144 (Supplement 1): 3817.

https://doi.org/10.1182/blood-2024-210779

Published: 2024

Journal Articles

Outcomes of Patients with Treated Secondary AML: A High Risk Subtype of AML Arising from Previously Treated Myeloid Neoplasms That Warrants an Independent Prognostic Designation

Jayastu Senapati, Hagop M. Kantarjian, Guillermo Garcia-Manero, Nicholas J. Short, Fadi G. Haddad, Naval Daver, Courtney D. DiNardo, Gautam Borthakur, Joseph E. Jabbour, Naveen Pemmaraju, Amin M. Alousi, Elizabeth J. Shpall, Alexandre Bazinet, Kelly S. Chien, Danielle Hammond, Sherry Pierce, Farhad Ravandi, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 4251.

https://doi.org/10.1182/blood-2024-208121

Published: 2024

Journal Articles

Evaluation of the Lethal Activity and Its Mechanism of Tasquinimod in Advanced Myeloproliferative Neoplasm (MPN) in Blastic Phase

Warren C. Fiskus, Lucia Masarova, Christopher Peter Mill, Christine Birdwell, Kaberi Das, John A. Davis, Hanxi Hou, Kevin Philip, Alicia Matthews, Taghi Manshouri, Surbhi Sharma, Tapan M. Kadia, Courtney D. DiNardo, Prithviraj Bose, Naveen Pemmaraju, Sanam Loghavi, Marie Törngren, Kapil N. Bhalla

Blood (2024) 144 (Supplement 1): 3142.

https://doi.org/10.1182/blood-2024-203947

Published: 2024

Journal Articles

Cohesin Complex Gene Mutated Acute Myeloid Leukemia (AML) Responds Favorably to Venetoclax Based Frontline Therapy

Blood (2024) 144 (Supplement 1): 4306.

https://doi.org/10.1182/blood-2024-208602

Published: 2024

Journal Articles

Reactivation of p53 in TP53 -Y220C Mutant AML: Mechanism of Action and Mechanism-Based Drug Combinations

Bing Z. Carter, Po Yee Mak, Baozhen Ke, Xiaogang Wu, Steffen Boettcher, Lauren B. Ostermann, Andrea Bedoy, Georgina Gener-Ricos, Jayastu Senapati, Courtney D. DiNardo, Anna Puzio-Kuter, Arnold Levine, Michael Andreeff

Blood (2024) 144 (Supplement 1): 4155.

https://doi.org/10.1182/blood-2024-208403

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Measurable residual disease intervention in AML: a new therapeutic horizon

FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML

Restoring p53 wild-type conformation in TP53 -Y220C–mutant acute myeloid leukemia

Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy

BLAST: a globally applicable and molecularly versatile survival model for chronic myelomonocytic leukemia

Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes

How I treat acute myeloid leukemia with differentiation therapy

Clonal landscape and clinical outcomes of telomere biology disorders: somatic rescue and cancer mutations

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

Causes of Death in Patients with Myelodysplastic Syndrome and Spliceosome Mutations

Impact of Flow Cytometry-Based Measurable Residual Disease Clearance Kinetics in Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy

Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

Final Results of a Phase II Study of Uproleselan Combined with Cladribine and Low-Dose Cytarabine for Patients with Treated Secondary Acute Myeloid Leukemia (ts-AML)

Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods

Outcomes of Patients with Treated Secondary AML: A High Risk Subtype of AML Arising from Previously Treated Myeloid Neoplasms That Warrants an Independent Prognostic Designation

Evaluation of the Lethal Activity and Its Mechanism of Tasquinimod in Advanced Myeloproliferative Neoplasm (MPN) in Blastic Phase

Cohesin Complex Gene Mutated Acute Myeloid Leukemia (AML) Responds Favorably to Venetoclax Based Frontline Therapy

Reactivation of p53 in TP53 -Y220C Mutant AML: Mechanism of Action and Mechanism-Based Drug Combinations

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only